Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.57 |
| ▸ | SUV39H1 | O43463 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | EP300 | Q09472 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.43 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.43 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verticillin A SCHEMBL18294765 | 1.00 | KMT2A (1.00) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin A SCHEMBL19275238 | 1.00 | KMT2A (1.00) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin A SCHEMBL15791200 | 1.00 | KMT2A (1.00) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin A SCHEMBL3291373 | 1.00 | KMT2A (1.00) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Gliocladine B SCHEMBL30076641 | 0.96 | KMT2A (0.91) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin A SCHEMBL29623110 | 0.96 | KMT2A (0.91) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Gliocladine A SCHEMBL29794217 | 0.96 | KMT2A (0.91) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin B SCHEMBL17975438 | 0.91 | KMT2A (0.82) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin B SCHEMBL5894069 | 0.91 | KMT2A (0.82) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin B SCHEMBL21497282 | 0.91 | KMT2A (0.82) | KMT2AEHMT2SUV39H1HIF1AEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448398-B2 | Semi-synthetic analogues of epipolythiodioxopiperazine alkaloids | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-21 | — | — | US | disclosed |
| CN-113402471-B | Siderophore compounds derived from plant endophytic fungi as well as preparation method and application of siderophore compounds | 华东理工大学 | 2022-09-13 | — | — | CN | disclosed |
| US-20220235072-A1 | SEMI-SYNTHETIC ANALOGUES OF EPIPOLYTHIODIOXOPIPERAZINE ALKALOIDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-28 | — | — | US | disclosed |
| EP-3986414-A1 | SEMI-SYNTHETIC ANALOGUES OF EPIPOLYTHIODIOXOPIPERAZINE ALKALOIDS | Ohio State Innovation Foundation (US) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448398-B2 | Semi-synthetic analogues of epipolythiodioxopiperazine alkaloids | EHMT1, EHMT2, KMT5A | KMT2A 7/4885EHMT2 2/4885SUV39H1 8/4885 |
| US-20220235072-A1 | SEMI-SYNTHETIC ANALOGUES OF EPIPOLYTHIODIOXOPIPERAZINE ALKALOIDS | EHMT1, EHMT2, KMT5A | KMT2A 7/4885EHMT2 2/4885SUV39H1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.